HRP20030624B1 - 6-substituted pyrido-pyrimidines - Google Patents

6-substituted pyrido-pyrimidines

Info

Publication number
HRP20030624B1
HRP20030624B1 HR20030624A HRP20030624A HRP20030624B1 HR P20030624 B1 HRP20030624 B1 HR P20030624B1 HR 20030624 A HR20030624 A HR 20030624A HR P20030624 A HRP20030624 A HR P20030624A HR P20030624 B1 HRP20030624 B1 HR P20030624B1
Authority
HR
Croatia
Prior art keywords
alkyl
cycloalkyl
hydrogen
aryl
heteroalkyl
Prior art date
Application number
HR20030624A
Other languages
English (en)
Croatian (hr)
Inventor
Jeffrey Chen Jian
Patrick Dunn James
Michael Goldstein David
Martin Stahl Christoph
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20030624A2 publication Critical patent/HRP20030624A2/hr
Publication of HRP20030624B1 publication Critical patent/HRP20030624B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR20030624A 2001-02-12 2003-08-01 6-substituted pyrido-pyrimidines HRP20030624B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26837501P 2001-02-12 2001-02-12
US33465401P 2001-11-30 2001-11-30
PCT/EP2002/001106 WO2002064594A2 (en) 2001-02-12 2002-02-04 6-substituted pyrido-pyrimidines

Publications (2)

Publication Number Publication Date
HRP20030624A2 HRP20030624A2 (en) 2005-06-30
HRP20030624B1 true HRP20030624B1 (en) 2007-03-31

Family

ID=26953040

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030624A HRP20030624B1 (en) 2001-02-12 2003-08-01 6-substituted pyrido-pyrimidines

Country Status (32)

Country Link
US (3) US6696566B2 (xx)
EP (1) EP1361880B1 (xx)
JP (1) JP4064818B2 (xx)
KR (1) KR100639772B1 (xx)
CN (1) CN100376571C (xx)
AR (1) AR035854A1 (xx)
AT (1) ATE305303T1 (xx)
AU (1) AU2002256615B2 (xx)
BR (1) BRPI0207172B8 (xx)
CA (1) CA2434834C (xx)
CZ (1) CZ20032416A3 (xx)
DE (1) DE60206363T2 (xx)
DK (1) DK1361880T3 (xx)
ES (1) ES2249574T3 (xx)
HK (1) HK1066170A1 (xx)
HR (1) HRP20030624B1 (xx)
HU (1) HU229604B1 (xx)
IL (2) IL156872A0 (xx)
JO (1) JO2410B1 (xx)
MA (1) MA26993A1 (xx)
MX (1) MXPA03007166A (xx)
MY (1) MY131518A (xx)
NO (1) NO326133B1 (xx)
NZ (1) NZ526961A (xx)
PA (1) PA8539201A1 (xx)
PE (1) PE20020976A1 (xx)
PL (1) PL366918A1 (xx)
RU (1) RU2269527C2 (xx)
SK (1) SK11322003A3 (xx)
WO (1) WO2002064594A2 (xx)
YU (1) YU63703A (xx)
ZA (1) ZA200305938B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
CA2434834C (en) 2001-02-12 2010-09-14 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
DK1470124T3 (da) * 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
AU2003215675B2 (en) 2002-04-03 2007-07-12 F. Hoffmann-La Roche Ag Imidazo fused compounds
RU2324695C2 (ru) * 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
CN1774250A (zh) * 2003-04-16 2006-05-17 霍夫曼-拉罗奇有限公司 作为治疗诸如类风湿性关节炎的炎性疾病的p38激酶抑制剂的(6-(苯氧基)-吡啶并[3,4-d]嘧啶-2-基)-胺衍生物
EP1685131B1 (en) * 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP1831215A1 (en) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2,3-d]pyrimidines as anti-inflamatory agents
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
US20090036472A1 (en) * 2005-02-02 2009-02-05 Palle Venkata P Azabicyclo derivatives as anti-inflammatory agents
WO2006119504A2 (en) * 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
DE602006010564D1 (de) * 2005-07-21 2009-12-31 Hoffmann La Roche Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
PL2099797T3 (pl) * 2005-08-09 2011-03-31 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
WO2008150260A1 (en) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
AU2008248296B2 (en) 2007-05-07 2011-12-01 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators, process for their preparation, and their pharmaceutical use
CN101679211A (zh) 2007-06-15 2010-03-24 霍夫曼-拉罗奇有限公司 用于制备3-氨基-戊-1,5-二醇的新方法
WO2009117156A1 (en) 2008-03-21 2009-09-24 Amgen Inc. Pyrazolo-pyrazinone compounds and methods of use thereof
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010046273A2 (en) * 2008-10-22 2010-04-29 F. Hoffmann-La Roche Ag Pyrimidinyl pyridone inhibitors of jnk
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
WO2011044535A2 (en) 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
UA123914C2 (uk) 2016-06-08 2021-06-23 Суппорт-Венче Гмбх Фармацевтичні комбінації для лікування раку
UA124804C2 (uk) 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
AU2017313296A1 (en) * 2016-08-17 2019-02-14 Support-Venture Gmbh Method of preventing or treating hearing loss
WO2018132550A1 (en) 2017-01-11 2018-07-19 The General Hospital Corporation Voltage gated sodium channel imaging agents
AU2018248578A1 (en) 2017-04-04 2019-10-17 Kinarus Ag Methods of preventing or treating ophthalmic diseases
JP2021501123A (ja) * 2017-08-31 2021-01-14 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Egfrおよび/またはher2の阻害剤ならびに使用方法
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US20210261547A1 (en) * 2018-06-27 2021-08-26 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
AU2019300135A1 (en) 2018-07-13 2021-01-28 Kinarus Ag Combinations of PPAR agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
US20230263803A1 (en) 2020-08-11 2023-08-24 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215216A (en) 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
AU598093B2 (en) 1987-02-07 1990-06-14 Wellcome Foundation Limited, The Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
ES2146782T3 (es) 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
EP0964864B1 (en) 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
TW458977B (en) * 1997-04-16 2001-10-11 Abbott Lab 6,7-disubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
AU7108398A (en) 1997-04-16 1998-11-11 Abbott Laboratories 5,7-disubstituted 4-aminopyrido{2,3-d}pyrimidine compounds and their use as adenosine kinase inhibitors
CN1252069A (zh) 1997-04-16 2000-05-03 艾博特公司 5,6,7-三取代的-4-氨基吡啶并[2,3-d]嘧啶化合物
PL344248A1 (en) 1998-05-26 2001-10-22 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
ES2258431T3 (es) 1999-08-02 2006-09-01 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de benzotiofeno.
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
MXPA02008535A (es) * 2000-03-06 2002-12-13 Warner Lambert Co Inhibidores de 5-alquilpirido (2.3-d) pirimidinas tirosina quinasa.
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
CA2434834C (en) 2001-02-12 2010-09-14 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
DK1470124T3 (da) * 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner

Also Published As

Publication number Publication date
KR20040018254A (ko) 2004-03-02
CN1503672A (zh) 2004-06-09
MXPA03007166A (es) 2003-11-18
CA2434834C (en) 2010-09-14
ATE305303T1 (de) 2005-10-15
US6696566B2 (en) 2004-02-24
BRPI0207172B1 (pt) 2019-04-09
EP1361880A2 (en) 2003-11-19
AR035854A1 (es) 2004-07-21
JP4064818B2 (ja) 2008-03-19
YU63703A (sh) 2006-05-25
WO2002064594A3 (en) 2003-01-09
CN100376571C (zh) 2008-03-26
DK1361880T3 (da) 2006-01-23
US7169794B2 (en) 2007-01-30
WO2002064594A2 (en) 2002-08-22
US20070135458A1 (en) 2007-06-14
RU2003125887A (ru) 2005-03-20
RU2269527C2 (ru) 2006-02-10
MY131518A (en) 2007-08-30
NO20033540L (no) 2003-08-11
AU2002256615B2 (en) 2007-09-13
ES2249574T3 (es) 2006-04-01
IL156872A (en) 2009-07-20
HUP0303458A2 (hu) 2004-01-28
IL156872A0 (en) 2004-02-08
CZ20032416A3 (cs) 2004-07-14
NO326133B1 (no) 2008-10-06
NO20033540D0 (no) 2003-08-11
US20040116698A1 (en) 2004-06-17
SK11322003A3 (en) 2004-10-05
HK1066170A1 (en) 2005-03-18
PA8539201A1 (es) 2004-08-31
PL366918A1 (en) 2005-02-07
BRPI0207172B8 (pt) 2021-05-25
MA26993A1 (fr) 2004-12-20
PE20020976A1 (es) 2002-10-29
JP2004525896A (ja) 2004-08-26
KR100639772B1 (ko) 2006-10-30
JO2410B1 (en) 2007-06-17
HU229604B1 (en) 2014-02-28
ZA200305938B (en) 2005-01-26
US20030171584A1 (en) 2003-09-11
HRP20030624A2 (en) 2005-06-30
EP1361880B1 (en) 2005-09-28
BR0207172A (pt) 2004-03-30
DE60206363T2 (de) 2006-07-06
NZ526961A (en) 2005-03-24
US7449581B2 (en) 2008-11-11
HUP0303458A3 (en) 2012-12-28
CA2434834A1 (en) 2002-08-22
DE60206363D1 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
HRP20030624B1 (en) 6-substituted pyrido-pyrimidines
HRP20170154T1 (hr) Analozi antibakterijskog aminoglikozida
AR037816A1 (es) Fenil derivados sustituidos
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
RS51394B (en) SUMPOR COMPOUNDS AS INHIBITORS OF NS3 SERINE PROTEASE HEPATITIS C VIRUS
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
EP1724262A4 (en) 1- (2H) -ISOCHINOLONDERIVAT
RS54638B1 (en) HCV SERIN PROTEASE INHIBITORS DERIVED FROM MACROCYCLIC PROLINE
RS50378B (sr) N-heterociklični derivati kao nos inhibitori
HRP20020247B1 (en) Antiviral compositions
AR069494A1 (es) Derivados de acidos fosfonicos
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
RS53734B1 (en) IAP INHIBITORS
AR062666A1 (es) Benzotriazoles como moduladores de quinasas
RS52451B (en) PHENYLPROPIONAMIDE COMPOUNDS AND THEIR USE
RS54348B1 (en) INHIBITORS NEPRILIZINA
AR025386A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
EA200870191A1 (ru) Новые производные циклической мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназ
ATE319446T1 (de) Neue prolinverbindungen als mikrobizide mittel
RS52489B (en) COMPOSITION AND ANTI-VIRUS ACTIVITY OF DERIVATIVES OF SUBSTITUTED AZAINDOLOXSOACETATE PIPERAZINE
AR040787A1 (es) 6-alcoxi-piridopirimidinas
HRP20100283T8 (en) Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
NO20082976L (no) Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
RS52762B (en) ALPHA KETOAMIDE COMPOUNDS AS CYSTEIN PROTEASE INHIBITORS
CO6140056A2 (es) Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081223

Year of fee payment: 8

PBON Lapse due to non-payment of renewal fee

Effective date: 20100205